Intermittent Low-Dose Ritlecitinib in Refractory Pediatric Alopecia Areata: A Case Report with Therapeutic Implications

The case report discusses the use of intermittent low-dose ritlecitinib in treating refractory pediatric alopecia areata. The study highlights the therapeutic implications of this treatment approach, particularly in pre-school children. The findings suggest that ritlecitinib may be a safe and effective option for managing alopecia areata in young patients who do not respond to conventional therapies. The report emphasizes the need for further research to confirm these results and to better understand the long-term safety and efficacy of ritlecitinib in this population.